NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Co-Diagnostics (NASDAQ:CODX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
Institutional and Insider Ownership
16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
NeuroOne Medical Technologies has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
| Co-Diagnostics | 1 | 2 | 1 | 0 | 2.00 |
NeuroOne Medical Technologies presently has a consensus price target of $11.67, suggesting a potential upside of 213.62%. Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 988.71%. Given Co-Diagnostics’ higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than NeuroOne Medical Technologies.
Earnings & Valuation
This table compares NeuroOne Medical Technologies and Co-Diagnostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $12.10 million | 2.65 | -$3.61 million | ($0.85) | -4.38 |
| Co-Diagnostics | $620,000.00 | 36.90 | -$46.90 million | ($15.77) | -0.39 |
NeuroOne Medical Technologies has higher revenue and earnings than Co-Diagnostics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NeuroOne Medical Technologies and Co-Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -68.35% | -98.33% | -69.85% |
| Co-Diagnostics | -6,760.63% | -164.92% | -141.15% |
Summary
NeuroOne Medical Technologies beats Co-Diagnostics on 10 of the 14 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
